Green Cross and Nanolek enter strategic partnership to commercialize biologics in Russia

26 March 2015

South Korean biopharma company Green Cross and Russian drugmaker Nanolek have entered into a strategic partnership for the commercialization of Green Cross’ biologics in the Russian market.

Nanolek will gain marketing authorizations and set up production of Green Cross’ biologics. Production will be organized at Nanolek’s facility, which complies with European Union Good Manufacturing Practice (GMP) standards and launched in December 2014.

The Russian pharma market is one of the most attractive in the emerging European countries, mainly due to size, but also a growing government investment in health care. Russia’s pharma market is expected to grow at twice the pace of the global pharma market, reaching an approximate market value of $43billion to $60 billion by 2020, according to the companies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK